Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 28 09 2019
accepted: 03 02 2020
entrez: 19 2 2020
pubmed: 19 2 2020
medline: 10 5 2020
Statut: epublish

Résumé

The maximum standardized uptake value (SUVmax) in 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) may be of prognostic significance for patients with malignant pleural mesothelioma (MPM). This retrospective study aimed to investigate the prognostic value of the SUVmax in patients with MPM. Medical records were retrospectively reviewed for the patients who were diagnosed with histopathologically proven MPM between 2009 and 2018 at Samsung Medical Center. For each patient, SUVmax was calculated for the primary lesion on PET/CT. To determine optimal cutoff values for predicting mortality, receiver operating characteristic curves were used. Among the 54 study patients, 34 (63.0%) had epithelioid subtype, 13 (24.1%) had sarcomatoid or biphasic subtype, and 7 (13.0%) had mesothelioma, not otherwise specified (NOS). The median overall survival (OS) was 8.7 months, and the median SUVmax was 9.9. The median values of SUVmax were 5.5 in patients with epithelioid subtype, 11.7 in those with sarcomatoid/biphasic subtype, and 13.3 in those with NOS subtype (P = 0.003). The optimal cutoff values of SUVmax to predict mortality were 10.1 in all patients, and 8.5 in patients with epithelioid subtype. In multivariate analysis, SUVmax was significantly associated with overall survival in all patients (P = 0.003) and in patients with epithelioid subtype (P = 0.012), but not in those with non-epithelioid subtype. SUVmax in PET/CT is an independent prognostic factor in patients with MPM, especially those with epithelioid subtype. The histologic subtype of MPM should be considered when evaluating the prognostic significance of SUVmax.

Identifiants

pubmed: 32069313
doi: 10.1371/journal.pone.0229299
pii: PONE-D-19-27290
pmc: PMC7028266
doi:

Substances chimiques

Radiopharmaceuticals 0
Fluorodeoxyglucose F18 0Z5B2CJX4D

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0229299

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Clin Radiol. 2019 Mar;74(3):207-215
pubmed: 30638733
Radiat Oncol. 2015 Dec 30;10:267
pubmed: 26715491
Eur J Nucl Med Mol Imaging. 2014 Feb;41(2):276-82
pubmed: 24057459
Lancet Oncol. 2017 May;18(5):623-630
pubmed: 28291584
Ann Oncol. 2013 Apr;24(4):1005-10
pubmed: 23136224
J Clin Oncol. 2003 Jul 15;21(14):2636-44
pubmed: 12860938
Lancet Oncol. 2011 Aug;12(8):763-72
pubmed: 21723781
Lancet Oncol. 2019 Feb;20(2):239-253
pubmed: 30660609
J Clin Oncol. 1998 Jan;16(1):145-52
pubmed: 9440736
J Thorac Cardiovasc Surg. 2006 Oct;132(4):763-8
pubmed: 17000285
J Thorac Oncol. 2016 Dec;11(12):2089-2099
pubmed: 27687963
Br J Cancer. 2014 Jul 15;111(2):220-6
pubmed: 24918816
J Clin Oncol. 2009 Jun 20;27(18):3007-13
pubmed: 19364962
Chest. 1998 Mar;113(3):723-31
pubmed: 9515850
J Thorac Oncol. 2007 Oct;2(10):957-65
pubmed: 17909360
Lancet Respir Med. 2019 Mar;7(3):260-270
pubmed: 30660511
Clin Lung Cancer. 2013 Jan;14(1):70-7
pubmed: 22658812
Eur J Cancer. 2012 May;48(8):1244-54
pubmed: 22330319
Eur J Nucl Med Mol Imaging. 2015 Apr;42(5):667-75
pubmed: 25403555
J Clin Oncol. 2006 Oct 1;24(28):4587-93
pubmed: 17008700
Thorac Surg Clin. 2016 Aug;26(3):359-75
pubmed: 27427530
J Thorac Oncol. 2016 Feb;11(2):249-55
pubmed: 26845118
Mol Imaging Biol. 2009 Nov-Dec;11(6):473-9
pubmed: 19330385
J Thorac Oncol. 2012 Jul;7(7):1192-7
pubmed: 22617244

Auteurs

Jun Hyeok Lim (JH)

Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Division of Pulmonology, Department of Internal Medicine, Inha University Hospital, Inha University School of Medicine, Incheon, South Korea.

Joon Young Choi (JY)

Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.

Yunjoo Im (Y)

Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.

Hongseok Yoo (H)

Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.

Byung Woo Jhun (BW)

Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.

Byeong-Ho Jeong (BH)

Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.

Hye Yun Park (HY)

Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.

Kyungjong Lee (K)

Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.

Hojoong Kim (H)

Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.

O Jung Kwon (OJ)

Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.

Joungho Han (J)

Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.

Myung-Ju Ahn (MJ)

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.

Jhingook Kim (J)

Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.

Sang-Won Um (SW)

Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH